UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

 

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended OctoberJanuary 31, 20142015

or

 

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to            

Commission file number 0-5286

 

 

KEWAUNEE SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 38-0715562

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

2700 West Front Street

Statesville, North Carolina

 28677-2927
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (704) 873-7202

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨  Accelerated filer ¨
Non-accelerated filer ¨  (Do not check if a smaller reporting company)  Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of December 8, 2014,March 9, 2015, the registrant had outstanding 2,626,8482,628,838 shares of Common Stock.

 

 

 


KEWAUNEE SCIENTIFIC CORPORATION

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED OCTOBERJANUARY 31, 20142015

 

     Page Number 

PART I. FINANCIAL INFORMATION

  

Item 1.

 

Financial Statements

  
 

Consolidated Statements of Operations (unaudited) – Three and sixnine months ended OctoberJanuary 31,
2015 and 2014 and 2013

   1  
 

Consolidated Statements of Comprehensive Income (unaudited) – Three and sixnine months ended OctoberJanuary 31,
2015 and 2014 and 2013

   2  
 

Consolidated Statement of Stockholders’ Equity – SixNine months ended OctoberJanuary  31, 20142015 (unaudited)

   3  
 

Consolidated Balance Sheets – OctoberJanuary 31, 20142015 (unaudited) and April 30, 2014

   4  
 

Consolidated Statements of Cash Flows (unaudited) – SixNine months ended OctoberJanuary 31, 20142015 and 20132014

   5  
 

Notes to Consolidated Financial Statements

   6  

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

   8  
 

Review by Independent Registered Public Accounting Firm

   11  
 

Report of Independent Registered Public Accounting Firm

   12  

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

   13  

Item 4.

 

Controls and Procedures

   13  

PART II. OTHER INFORMATION

  

Item 6.

 

Exhibits

   14  

SIGNATURE

   15  

 

i


Part 1. Financial Information

 

Item 1.Financial Statements

Kewaunee Scientific Corporation

Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share data)

 

  Three months ended
October 31
 Six months ended
October 31
   Three months ended
January 31
 Nine months ended
January 31
 
  2014 2013 2014 2013   2015 2014 2015 2014 

Net sales

  $30,258   $26,098   $60,792   $58,101    $27,754   $26,013   $88,546   $84,114  

Costs of products sold

   24,436   21,205   48,822   46,632     23,298   21,302   72,120   67,934  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

Gross profit

   5,822    4,893    11,970    11,469   4,456   4,711   16,426   16,180  

Operating expenses

   3,950    3,759    8,298    7,903   3,872   3,773   12,170   11,676  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

Operating earnings

   1,872    1,134    3,672    3,566   584   938   4,256   4,504  

Other income

   125    90    251    170   134   95   385   265  

Interest expense

   (102  (72  (183  (160 (91 (116 (274 (276
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

Earnings before income taxes

   1,895    1,152    3,740    3,576   627   917   4,367   4,493  

Income tax expense

   667    406    1,252    1,213   109   292   1,361   1,505  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

Net earnings

   1,228    746    2,488    2,363   518   625   3,006   2,988  

Less: net earnings attributable to the noncontrolling interest

   26    21    52    51   34   21   86   72  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

Net earnings attributable to Kewaunee Scientific Corporation

  $1,202   $725   $2,436   $2,312  $484  $604  $2,920  $2,916  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

Net earnings per share attributable to Kewaunee Scientific Corporation stockholders

     

Basic

  $0.46   $0.28   $0.93   $0.89  $0.18  $0.23  $1.11  $1.12  

Diluted

  $0.45   $0.28   $0.92   $0.89  $0.18  $0.22  $1.10  $1.11  

Weighted average number of common shares outstanding

     

Basic

   2,626    2,606    2,623    2,601   2,628   2,615   2,625   2,606  

Diluted

   2,659    2,633    2,655    2,618   2,659   2,645   2,656   2,627  

See accompanying notes to consolidated financial statements.

Kewaunee Scientific Corporation

Consolidated Statements of Comprehensive Income

(Unaudited)

(in thousands)

 

  Three months ended
October 31
 Six months ended
October 31
   Three months ended
January 31
 Nine months ended
January 31
 
  2014 2013 2014 2013   2015 2014 2015 2014 

Net earnings

  $1,228   $746   $2,488   $2,363    $518   $625   $3,006   $2,988  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

Other comprehensive income (loss), net of tax:

     

Foreign currency translation adjustments

   (126  91    (116  (433 (130 (133 (246 (566

Change in fair value of cash flow hedge

   (11  (23  2    42   (17 28   (15 70  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

Other comprehensive income (loss)

   (137  68    (114  (391 (147 (105 (261 (496
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

Comprehensive income, net of tax

   1,091    814    2,374    1,972   371   520   2,745   2,492  

Less: comprehensive income attributable to the noncontrolling interest

   26    21    52    51   34   21   86   72  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

Comprehensive income attributable to Kewaunee Scientific Corporation

  $1,065   $793   $2,322   $1,921  $337  $499  $2,659  $2,420  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

See accompanying notes to consolidated financial statements.

Kewaunee Scientific Corporation

Consolidated Statement of Stockholders’ Equity

(Unaudited)

(in thousands)

 

$ in thousands, except per share amounts

  Common
Stock
   Additional
Paid-in
Capital
   Treasury
Stock
 Retained
Earnings
 Accumulated
Other
Comprehensive
Income (Loss)
 Total
Stockholders’
Equity
   Common
Stock
   Additional
Paid-in
Capital
   Treasury
Stock
 Retained
Earnings
 Accumulated
Other
Comprehensive
Income (Loss)
 Total
Stockholders’
Equity
 

Balance at April 30, 2014

  $6,557    $1,642    $(57 $32,090   $(6,273 $33,959    $6,557    $1,642    $(57 $32,090   $(6,273 $33,959  

Net earnings attributable to Kewaunee Scientific Corporation

   —      —      —    2,436    —    2,436     —       —       —     2,920    —     2,920  

Other comprehensive income (loss)

   —      —      —     —    (114 (114   —       —       —      —     (261 (261

Cash dividends paid, $0.23 per share

   —      —      —    (603  —    (603

Stock options exercised, 22,825 shares

   18     10     25    —     —    53  

Cash dividends paid, $0.35 per share

   —       —       —     (919  —     (919

Stock options exercised, 29,075 shares

   23     6     25    —      —     54  

Stock based compensation

   —      108     —     —     —    108     —       154     —      —      —     154  

Purchase of treasury stock, 1,159 shares

   —      —      (21  —     —    (21   —       —       (21  —      —     (21
  

 

   

 

   

 

  

 

  

 

  

 

   

 

   

 

   

 

  

 

  

 

  

 

 

Balance at October 31, 2014

  $6,575    $1,760    $(53 $33,923   $(6,387 $35,818  

Balance at January 31, 2015

$6,580  $1,802  $(53$34,091  $(6,534$35,886  
  

 

   

 

   

 

  

 

  

 

  

 

   

 

   

 

   

 

  

 

  

 

  

 

 

See accompanying notes to consolidated financial statements.

Kewaunee Scientific Corporation

Consolidated Balance Sheets

(in thousands)

 

  October 31,
2014
 April 30,
2014
   January 31,
2015
 April 30,
2014
 
  (Unaudited)     (Unaudited)   

Assets

      

Current Assets:

      

Cash and cash equivalents

  $4,863   $6,248    $3,863   $6,248  

Restricted cash

   2,869   368     2,524   368  

Receivables, less allowance

   24,074   23,473     25,062   23,473  

Inventories

   12,199   11,938     12,430   11,938  

Deferred income taxes

   644   646     655   646  

Prepaid expenses and other current assets

   1,224   680  ��  1,048   680  
  

 

  

 

   

 

  

 

 

Total Current Assets

   45,873    43,353   45,582   43,353  

Property, plant and equipment, at cost

   47,915    46,391   48,409   46,391  

Accumulated depreciation

   (32,982  (31,821 (33,604 (31,821
  

 

  

 

   

 

  

 

 

Net Property, Plant and Equipment

   14,933    14,570   14,805   14,570  

Deferred income taxes

   1,428    1,385   1,447   1,385  

Other

   3,595    3,409   3,616   3,409  
  

 

  

 

   

 

  

 

 

Total Other Assets

   5,023    4,794   5,063   4,794  
  

 

  

 

   

 

  

 

 

Total Assets

  $65,829   $62,717  $65,450  $62,717  
  

 

  

 

   

 

  

 

 

Liabilities and Equity

   

Current Liabilities:

   

Short-term borrowings and interest rate swap

  $941   $3,150  $1,036  $3,150  

Current portion of long-term debt

   421    421   421   421  

Accounts payable

   11,405    8,542   12,093   8,542  

Employee compensation and amounts withheld

   2,021    2,000   1,358   2,000  

Deferred revenue

   238    137   296   137  

Other accrued expenses

   2,960    1,913   3,026   1,913  
  

 

  

 

   

 

  

 

 

Total Current Liabilities

   17,986    16,163   18,230   16,163  

Long-term debt

   3,982    4,192   3,876   4,192  

Accrued pension and deferred compensation costs

   7,769    7,250   7,152   7,250  

Other non-current liabilities

   —     888   —    888  
  

 

  

 

   

 

  

 

 

Total Liabilities

   29,737    28,493   29,258   28,493  

Commitments and Contingencies

   

Equity:

   

Common Stock

   6,575    6,557   6,580   6,557  

Additional paid-in-capital

   1,760    1,642   1,802   1,642  

Retained earnings

   33,923    32,090   34,091   32,090  

Accumulated other comprehensive loss

   (6,387  (6,273 (6,534 (6,273

Common stock in treasury, at cost

   (53  (57 (53 (57
  

 

  

 

   

 

  

 

 

Total Kewaunee Scientific Corporation Stockholders’ Equity

   35,818    33,959   35,886   33,959  

Noncontrolling interest

   274    265   306   265  
  

 

  

 

   

 

  

 

 

Total Equity

   36,092    34,224   36,192   34,224  
  

 

  

 

   

 

  

 

 

Total Liabilities and Equity

  $65,829   $62,717  $65,450  $62,717  
  

 

  

 

   

 

  

 

 

See accompanying notes to consolidated financial statements.

Kewaunee Scientific Corporation

Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

 

  Six months ended
October 31
   Nine months ended
January 31
 
  2014 2013   2015 2014 

Cash flows from operating activities:

      

Net earnings

  $2,488   $2,363    $3,006   $2,988  

Adjustments to reconcile net earnings to net cash provided by operating activities:

      

Depreciation

   1,263   1,248     1,900   1,846  

Bad debt provision

   4   71     34   109  

Stock based compensation expense

   108   125     154   186  

Provision for deferred income tax expense

   (41 (42   (71 (80

Change in assets and liabilities:

      

(Increase) decrease in receivables

   (605 5,363     (1,623 3,805  

(Increase) decrease in inventories

   (261 29     (492 696  

Increase (decrease) in accounts payable and other accrued expenses

   3,931   (2,198   4,022   (2,127

Increase (decrease) in deferred revenue

   101   (420   159   (317

Other, net

   (226 (343   (750 126  
  

 

  

 

   

 

  

 

 

Net cash provided by operating activities

   6,762    6,196   6,339   7,232  

Cash flows from investing activities:

   

Capital expenditures

   (1,626  (1,188 (2,135 (1,614

(Increase) decrease in restricted cash

   (2,501  88   (2,156 14  
  

 

  

 

   

 

  

 

 

Net cash used in investing activities

   (4,127  (1,100 (4,291 (1,600

Cash flows from financing activities:

   

Dividends paid

   (603  (547 (919 (834

Dividends paid to noncontrolling interest in subsidiaries

   (38  (38 (38 (38

Decrease in short-term borrowings and interest rate swap

   (2,209  (4,278 (2,114 (2,828

Proceeds from long-term debt

   —     5,000   —    5,000  

Payments on long-term debt

   (210  (3,643 (316 (3,748

Payment toward purchase of noncontrolling interest in subsidiary

   (888  (1,780 (888 (1,780

Net proceeds from exercise of stock options (including tax benefit)

   32    59   33   59  
  

 

  

 

   

 

  

 

 

Net cash used in financing activities

   (3,916  (5,227 (4,242 (4,169

Effect of exchange rate changes on cash

   (104  (396 (191 (616
  

 

  

 

   

 

  

 

 

Decrease in cash and cash equivalents

   (1,385  (527

(Decrease) increase in cash and cash equivalents

 (2,385 847  

Cash and cash equivalents, beginning of period

   6,248    5,811   6,248   5,811  
  

 

  

 

   

 

  

 

 

Cash and cash equivalents, end of period

  $4,863   $5,284  $3,863  $6,658  
  

 

  

 

   

 

  

 

 

Supplemental Disclosure of Cash Flow Information

   

Purchase of noncontrolling interest in subsidiary –

Other accrued expenses and other non-current liabilities

  $—    $1,775  $—   $1,775  
  

 

  

 

   

 

  

 

 

See accompanying notes to consolidated financial statements.

Kewaunee Scientific Corporation

Notes to Consolidated Financial Statements

(unaudited)

A.Financial Information

The unaudited interim consolidated financial statements of Kewaunee Scientific Corporation (the “Company”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”).Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These interim consolidated financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of these financial statements and should be read in conjunction with the consolidated financial statements and notes included in the Company’s 2014 Annual Report to Stockholders. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. The consolidated balance sheet as of April 30, 2014 included in this interim period filing has been derived from the audited financial statements at that date, but does not include all of the information and related notes required by generally accepted accounting principles (GAAP) for complete financial statements.

The preparation of the interim consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

B.Earnings Per Share

Basic earnings per share is based on the weighted average number of common shares outstanding during the three and sixnine month periods. Diluted earnings per share reflects the assumed exercise and conversion of outstanding options under the Company’s stock option plans, except when options have an anti-dilutive effect. Options to purchase 70,800 shares were not included in the computation of diluted earnings per share for the three and sixnine month periods ended OctoberJanuary 31, 2014,2015, because the option exercise prices were greater than the average market price of the common shares at that date, and accordingly, such options would have an antidilutive effect. Options to purchase 48,05036,600 shares were not included in the computation of diluted earnings per share for the three and sixnine month periods ended OctoberJanuary 31, 2013,2014, because the effect would be anti-dilutive.

C.Inventories

Inventories consisted of the following (in thousands):

 

  October 31, 2014   April 30, 2014   January 31, 2015   April 30, 2014 

Finished products

  $3,277    $2,909    $3,137    $2,909  

Work in process

   1,570     1,550     1,412     1,550  

Raw materials

   7,352     7,479     7,881     7,479  
  

 

   

 

   

 

   

 

 
  $12,199    $11,938  $12,430  $11,938  
  

 

   

 

   

 

   

 

 

For interim reporting, LIFO inventories are computed based on year-to-date quantities and interim changes in price levels. Changes in quantities and price levels are reflected in the interim consolidated financial statements in the period in which they occur.

D.Segment Information

The following table provides financial information by business segments for the three and sixnine months ended OctoberJanuary 31, 20142015 and 20132014 (in thousands):

 

  Domestic
Operations
   International
Operations
   Corporate Total   Domestic
Operations
   International
Operations
   Corporate Total 

Three months ended October 31, 2014

       

Three months ended January 31, 2015

       

Revenues from external customers

  $23,629    $6,629    $—    $30,258    $20,025    $7,729    $ —     $27,754  

Intersegment revenues

   782     374     (1,156  —      501     697     (1,198  —    

Earnings (loss) before income taxes

   2,059     769     (933 1,895     264     1,046     (683 627  

Three months ended October 31, 2013

       

Three months ended January 31, 2014

       

Revenues from external customers

  $22,061    $4,037    $—    $26,098    $21,544    $4,469    $ —     $26,013  

Intersegment revenues

   532     762     (1,294  —      214     456     (670  —    

Earnings (loss) before income taxes

   1,382     584     (814 1,152     1,227     678     (988 917  

  Domestic
Operations
   International
Operations
   Corporate Total   Domestic
Operations
   International
Operations
   Corporate Total 

Six months ended October 31, 2014

       

Nine months ended January 31, 2015

       

Revenues from external customers

  $47,877    $12,915    $—    $60,792    $67,902    $20,644    $ —     $88,546  

Intersegment revenues

   906     906     (1,812  —      1,407     1,603     (3,010  —    

Earnings (loss) before income taxes

   4,262     1,473     (1,995 3,740     4,526     2,519     (2,678 4,367  

Six months ended October 31, 2013

       

Nine months ended January 31, 2014

       

Revenues from external customers

  $49,134    $8,967    $—    $58,101    $70,678    $13,436    $ —     $84,114  

Intersegment revenues

   1,936     1,248     (3,184  —      2,150     1,704     (3,854  —    

Earnings (loss) before income taxes

   4,564     1,141     (2,129 3,576     5,791     1,819     (3,117 4,493  

E.Defined Benefit Pension Plans

The Company has non-contributory defined benefit pension plans covering substantially all salaried and hourly employees.plans. These plans were amended as of April 30, 2005, no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. The Company did not make any contributionsContributions of $775,000 were paid to the plans during the sixnine months ended OctoberJanuary 31, 2014. The2015, and the Company expectsdoes not expect any contributions to make contributions of $775,000be paid to the plans in December 2014 forduring the remainder of the fiscal year 2015.year. Contributions of $300,000 were made during the sixnine months ended OctoberJanuary 31, 2013.2014.

Pension expense consisted of the following (in thousands):

 

  Three months ended
October 31, 2014
 Three months ended
October 31, 2013
   Three months ended
January 31, 2015
   Three months ended
January 31, 2014
 

Service cost

  $-0-   $-0-    $-0-    $-0-  

Interest cost

   225   217     223     214  

Expected return on plan assets

   (337 (324   (331   (321

Recognition of net loss

   233   288     233     286  
  

 

  

 

   

 

   

 

 

Net periodic pension expense

  $121   $181  $125  $179  
  

 

  

 

   

 

   

 

 
  Six months ended
October 31, 2014
 Six months ended
October 31, 2013
   Nine months ended
January 31, 2015
   Nine months ended
January 31, 2014
 

Service cost

  $-0-   $-0-    $-0-    $-0-  

Interest cost

   447   429     670     643  

Expected return on plan assets

   (662 (641   (993   (962

Recognition of net loss

   467   571     700     857  
  

 

  

 

   

 

   

 

 

Net periodic pension expense

  $252   $359  $377  $538  
  

 

  

 

   

 

   

 

 

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Company’s 2014 Annual Report to Stockholders contains management’s discussion and analysis of financial condition and results of operations as of and for the year ended April 30, 2014. The following discussion and analysis describes material changes in the Company’s financial condition since April 30, 2014. The analysis of results of operations compares the three and sixnine months ended OctoberJanuary 31, 20142015 with the comparable periods of the prior year.

Results of Operations

Sales for the three months ended OctoberJanuary 31, 20142015 were $30,258,000,$27,754,000, an increase of 16%7% from sales of $26,098,000$26,013,000 in the comparable period of the prior year. Sales from Domestic Operations were $23,629,000, up$20,025,000, down from $22,061,000$21,544,000 in the comparable period of the prior year. The increasedecrease in Domestic Operations sales resulted from the challenging domestic sales reflects increased demandlaboratory construction marketplace, particularly for the Company’s products in certain geographic areas of the country.educational laboratory construction projects. Sales from International Operations were $6,629,000,$7,729,000, up from $4,037,000$4,469,000 in the comparable period of the prior year, as the Company continues to realize new sales opportunitiesbenefited from shipments of several large international orders received in the international marketplace.earlier periods.

Sales for the sixnine months ended OctoberJanuary 31, 20142015 were $60,792,000,$88,546,000, up 5% from sales of $58,101,000$84,114,000 in the same period last year. Domestic Operations sales for the six-monthnine-month period were $47,877,000,$67,902,000, down from sales of $49,134,000$70,678,000 in the same period last year.year, due to the challenging laboratory construction marketplace. International Operations sales were $12,915,000,$20,644,000, up 44%54% from sales of $8,967,000$13,436,000 in the same period last year. The increase in International Operations sales resulted from the Company continuing to realize new sales opportunitiesyear, as several large orders taken in the international marketplace.prior year were shipped in the current year period.

The order backlog was $78.0 million at January 31, 2015, as compared to $84.5 million at October 31, 2014 as compared to $82.7and $69.8 million at JulyJanuary 31, 2014 and $69.5 million at October 31, 2013.2014.

The gross profit margin for the three months ended OctoberJanuary 31, 20142015 was 19.2%16.1% of sales, as compared to 18.7%18.1% of sales in the comparable quarter of the prior year. The increasedecrease in the margin was the result of cost reduction activities, partially offset byhighly-competitive pricing in the domestic marketplace and an unfavorable impact of a change in product mix for international sales.mix. The gross profit margin for the sixnine months ended OctoberJanuary 31, 20142015 was 19.7%18.6% of sales, unchanged fromas compared to 19.2% in the comparable period of the prior year.

Operating expenses for the three months ended OctoberJanuary 31, 20142015 were $3,950,000,$3,872,000, or 13.1%14.0% of sales, as compared to $3,759,000,$3,773,000, or 14.4%14.5% of sales, in the comparable period of the prior year. Operating expenses for the three months ended OctoberJanuary 31, 20142015 reflect an increase of $118,000$47,000 in sales and marketing expenses, an increase of $235,000 for the Company’s International Operations, and an increase of $180,000$95,000 in incentive compensation,salaries and benefits, partially offset by decreasesa $54,000 reduction in defined benefit pension expense, of $60,000a $275,000 reduction in incentive compensation and an $8,000 reduction in bad debt expense of $64,000.expense. Operating expenses for the sixnine months ended OctoberJanuary 31, 20142015 were $8,298,000,$12,170,000, or 13.6%13.7% of sales, as compared to $7,903,000,$11,676,000, or 13.6%13.9% of sales in the comparable period of the prior year. Operating expenses for the sixnine months ended OctoberJanuary 31, 20142015 reflect an increase of $466,000$243,000 in sales and marketing expenses, an increase of $213,000$453,000 in operating expenses for the Company’s International Operations, and an increase of $61,000$191,000 in incentive compensation,salaries and benefits, partially offset by a decrease in corporate and administrative salaries of $198,000, a $107,000$161,000 reduction in defined benefit pension expense, a $214,000 reduction in incentive compensation and a $67,000$75,000 reduction in bad debt expense.

Interest expense was $102,000$91,000 and $183,000$274,000 for the three and sixnine months ended OctoberJanuary 31, 2014,2015, respectively, as compared to $72,000$116,000 and $160,000$276,000 for the comparable periods of the prior year. The increasesdecreases for the current year periods resulted primarily from higherlower borrowing levels.

Income tax expense of $667,000$109,000 was recorded for the three months ended OctoberJanuary 31, 2014,2015, as compared to income tax expense of $406,000$292,000 recorded for the comparable period of the prior year. Income tax expense of $1,252,000$1,361,000 was recorded for the sixnine months ended OctoberJanuary 31, 2014,2015, as compared to income tax expense of $1,213,000$1,505,000 recorded for the comparable period of the prior year. The effective tax rate was 35.2%rates were 17.4% and 31.8% for each of the three-month periods ended OctoberJanuary 31, 2015 and 2014, and 2013.respectively. The effective tax rates were 33.5%31.2% and 33.9%33.5% for the nine months ended January 31, 2015 and 2014, respectively. The effective tax rate for the current three month period was lower than the comparable period of the prior year primarily due to the impact of the reinstatement of the federal research and development (R&D) tax credit in January 2015 retroactive to 2014. The cumulative impact of these credits for the first six months ended October 31, 2014 and 2013, respectively. The differences betweenof the fiscal year was considered in the third quarter effective rate calculation. Additionally, the effective tax rates in eachall of thesethe reported periods resulted primarily fromwere impacted by the varying ratios of pretax earnings attributable to subsidiaries located in geographic locations with lower income tax rates. Also, the effective tax rates in each of the periods of the current year and prior year were reduced from statutory tax rates by the favorable impact of state and federal tax credits.

Noncontrolling interests related to the Company’s subsidiary that is not 100% owned by the Company reduced net earnings by $26,000$34,000 for the three months ended OctoberJanuary 31, 2014,2015, as compared to $21,000 for the comparable period of the prior year. Net earnings were reduced by $52,000$86,000 and $51,000$72,000 for the sixnine months ended OctoberJanuary 31, 20142015 and 2013,2014, respectively. The changes in the amounts between each of these periods were directly attributable to changes in the amounts of net income reported for the Company’s one subsidiary that is not 100% owned by the Company.

Net earnings of $1,202,000,$484,000, or $0.45$0.18 per diluted share, were reported for the three months ended OctoberJanuary 31, 2014,2015, compared to net earnings of $725,000,$604,000, or $0.28$0.22 per diluted share, in the prior year period. Net earnings of $2,436,000,$2,920,000, or $0.92$1.10 per diluted share, were reported for the sixnine months ended OctoberJanuary 31, 2014,2015, compared to net earnings of $2,312,000,$2,916,000, or $0.89$1.11 per diluted share, for the same period last year.

Liquidity and Capital Resources

Historically, the Company’s principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company’s revolving credit facility. Additionally, certain machinery and equipment are financed by non-cancellable operating leases or capital leases. The Company believes that these sources will be sufficient to support ongoing business requirements in the current fiscal year, including capital expenditures.

The Company had working capital of $27,887,000$27,352,000 at OctoberJanuary 31, 2014,2015, compared to $27,190,000 at April 30, 2014. The ratio of current assets to current liabilities was 2.6-to-1.02.5-to-1.0 at OctoberJanuary 31, 2014,2015, compared to 2.7-to-1.0 at April 30, 2014. At OctoberJanuary 31, 2014,2015, advances of $699,000$272,000 were outstanding under the Company’s bank revolving credit facility, as compared to advances of $2,900,000 outstanding as of April 30, 2014. The Company had standby letters of credit outstanding of $4,210,000 at OctoberJanuary 31, 2014,2015, compared to $4,305,000 at April 30, 2014. Amounts available under the $20 million revolving credit facility were $15.1$15.5 million and $12.8 million at OctoberJanuary 31, 20142015 and April 30, 2014, respectively. Total bank borrowings were $5,102,000$5,333,000 at OctoberJanuary 31, 2014,2015, as compared to $7,763,000 at April 30, 2014.

The Company’s operations provided cash of $6,762,000$6,339,000 during the sixnine months ended OctoberJanuary 31, 2014.2015. Cash was primarily provided from earnings and an increase in accounts payable and other accrued expenses of $3,931,000,$4,022,000, which was partially offset by an increase in accounts receivable of $605,000,$1,623,000, and an increase in inventories of $261,000.$492,000. The large increase in accounts payable and accrued expenses was primarily attributable to the start-up of a large international project.project during the current year. The Company’s operations provided cash of $6,196,000$7,232,000 during the sixnine months ended OctoberJanuary 31, 2013,2014, with cash primarily provided from earnings and a decrease in accounts receivable of $5,363,000,$3,805,000, partially offset by a decrease in accounts payable and accrued expenses of $2,198,000.$2,127,000.

During the sixnine months ended OctoberJanuary 31, 2014,2015, net cash of $4,127,000$4,291,000 was used in investing activities for capital expenditures of $1,626,000$2,135,000 and an increase in restricted cash of $2,501,000.$2,156,000. The increase in restricted cash resulted from the Company’s pledge of cash to support bank guarantees required for the start-up of a large international project. This compares to the net use of cash of $1,100,000$1,600,000 for investing activities in the comparable period of the prior year for capital expenditures of $1,188,000,$1,614,000, offset by a decrease in restricted cash of $88,000.$14,000.

The Company’s financing activities used cash of $3,916,000$4,242,000 during the sixnine months ended OctoberJanuary 31, 20142015 for the payment of $888,000 for the second installment toward the purchase of the noncontrolling interest in a subsidiary, $2,209,000$2,114,000 for repayment of short-term borrowings, cash dividends of $603,000$919,000 paid to stockholders, cash dividends of $38,000 paid to minority interest holders, and payments of $210,000$316,000 on long-term debt. The Company’s financing activities used cash of $5,227,000$4,169,000 during the sixnine months ended OctoberJanuary 31, 20132014 for payment of $1,780,000 toward the purchase of the noncontrolling interest in a subsidiary, repayment of short-term borrowings of $4,278,000,$2,828,000, cash dividends of $547,000$834,000 paid to stockholders, and cash dividends of $38,000 paid to minority interest holders. This was partially offset by a net increase in long-term debt of $1,357,000$1,252,000 in conjunction with the replacement of the Company’s long-term loans with a new lender.

Outlook

The Company’s ability to predict future demand for its products continues to be limited given its role as subcontractor or supplier to dealers for subcontractors. Demand for the Company’s products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. The Company’s earnings are also impacted by fluctuations in prevailing pricing for projects in the laboratory construction marketplace and increased costs of raw materials, including stainless steel, wood, and epoxy resin, and whether the Company is able to increase product prices to customers in amounts that correspond to such increases without materially and adversely affecting sales. Additionally, since prices are normally quoted on a firm basis in the industry, the Company bears the burden of possible increases in labor and material costs between the quotation of an order and delivery of a product. The Company is also unable to predict the strength of the global economic recovery and its short-term and long-term impact on the Company’s operations and the markets in which it competes. Looking forward, the Company expects the second half of fiscal year 2015 to be profitablesales and earnings for the Company.fourth quarter to improve over the third quarter of the current fiscal year.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This report contains statements that the Company believes to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this report, including statements regarding the Company’s future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “predict,” “believe” and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to, competitive and general economic conditions, both domestically and internationally; changes in customer demands; dependence on customers’ required delivery schedules; risks related to fluctuations in the Company’s operating results from quarter to quarter; risks related to international operations, including foreign currency

fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; and acts of terrorism, war, governmental action, natural disasters and other Force Majeure events. Many important factors that could cause such a difference are described under the caption “Risk Factors” in Item 1A in the Company’s 2014 Annual Report on Form 10-K. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

REVIEW BY INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

A review of the interim consolidated financial information included in this Quarterly Report on Form 10-Q for each of the three and sixnine month periods ended OctoberJanuary 31, 20142015 and OctoberJanuary 31, 20132014 has been performed by Cherry Bekaert LLP, the Company’s independent registered public accounting firm. Their report on the interim consolidated financial information follows.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have reviewed the accompanying consolidated balance sheet of Kewaunee Scientific Corporation and its subsidiaries (the “Company”) as of OctoberJanuary 31, 2014,2015, the related consolidated statements of operations, and comprehensive income for the three-month and six-monthnine-month periods ended OctoberJanuary 31, 20142015 and 2013,2014, the related consolidated statement of stockholders’ equity for the six-monthnine-month period ended OctoberJanuary 31, 2014,2015, and the related consolidated statements of cash flows for the six-monthnine-month periods ended OctoberJanuary 31, 20142015 and 2013.2014. These interim consolidated financial statements are the responsibility of the Company’s management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the interim consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet as of April 30, 2014, and the related consolidated statements of operations, comprehensive income and stockholders’ equity, and cash flows for the year then ended (not presented herein) and in our report dated July 17, 2014, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of April 30, 2014 is fairly stated in all material respects in relation to the consolidated financial statement from which it has been derived.

 

/s/ Cherry Bekaert LLP

Charlotte, North Carolina

December 12, 2014March 13, 2015

Item 3.Quantitative and Qualitative Disclosures About Market Risk

There are no material changes to the disclosures made on this matter in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2014.

 

Item 4.Controls and Procedures

(a) Evaluation of disclosure controls and procedures

An evaluation was performed under the supervision and with the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of OctoberJanuary 31, 2014.2015. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that, as of OctoberJanuary 31, 2014,2015, the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.

(b) Changes in internal controls

There was no significant change in the Company’s internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

 

Item 6.Exhibits

 

    3.1

  31.1
Bylaws (As amended as of August 27, 2014)(1)

  10.1 *

Restated and Amended Change of Control Employment Agreement, dated August 27, 2014, between the Company and David M. Rausch.(1)

  10.2 *

Extension Agreement, dated August 27, 2014, with respect to the Change of Control Employment Agreement of D. Michael Parker. (1)

  10.3 *

Extension Agreement, dated August 27, 2014, with respect to the Change of Control Employment Agreement of Kurt P. Rindoks.(1)

  10.4 *

Extension Agreement, dated August 27, 2014, with respect to the Change of Control Employment Agreement of Keith D. Smith.(1)

  10.5 *

Extension Agreement, dated August 27, 2014, with respect to the Change of Control Employment Agreement of Elizabeth D. Phillips.(1)

  10.6 *

Extension Agreement, dated August 27, 2014, with respect to the Change of Control Employment Agreement of Dana L. Dahlgren.(1)

  10.7 *

First Amendment to the Re-Established Retirement Plan for Salaried Employees of Kewaunee Scientific Corporation(1)

  10.8 *

First Amendment to the Re-Established Retirement Plan for Hourly Employees of Kewaunee Scientific Corporation(1)

  10.9 *

Amendment No. One to the Kewaunee Scientific Corporation Pension Equalization Plan(1)

  10.10 *

Amendment No. One to the Kewaunee Scientific Corporation 401 Plus Executive Deferred Compensation Plan(1)

  31.1

Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

  31.2

Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

  32.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

  32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Extension Label Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

*The referenced exhibit is a management contract or compensatory plan or arrangement.
(1)Filed as an exhibit to the Kewaunee Scientific Corporation Current Report on Form 8-K (Commission file No. 0-5286) filed on September 2, 2014 and incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

KEWAUNEE SCIENTIFIC CORPORATION
                            (Registrant)

Date: December 12, 2014

March 13, 2015By

/s/ D. Michael Parker

D. Michael Parker
(As duly authorized officer and Senior Vice President, Finance and Chief Financial Officer)

 

15